Key result
Low-molecular-weight heparin treatment during pregnancy in women with inherited thrombophilia resulted in 0% fetal loss compared to 76.9% in their previous untreated pregnancies.
Why the study?
Does LMWH improve pregnancy outcomes in women with inherited thrombophilia and a history of thromboembolic events or poor obstetric outcomes?
Population
38 women with inherited thrombophilia and a history of thromboembolic events and/or poor obstetric outcome
Comparison
Low-molecular-weight heparin, mostly enoxaparin… vs Previous untreated pregnancies in the same women
Design
Cohort
Follow-up
Until 4-6 weeks in puerperium
Authors
Loading...
May support LMWH consideration in high-risk thrombophilia pregnancies; leaves open confirmation by randomized trials before practice change.
Cohort (n=38)
Does LMWH improve pregnancy outcomes in women with inherited thrombophilia and a history of thromboembolic events or poor obstetric outcomes?
Absolute Event Rate: 0% vs 76.9%
LMWH treatment during pregnancy in women with inherited thrombophilia and prior poor obstetric outcomes or thromboembolic events significantly improves fetal survival and birth weight without increasing bleeding risk.
Carolis et al. (2006) conducted a cohort in Inherited thrombophilia (n=38). Low-molecular-weight heparin (LMWH) vs. Previous untreated pregnancies was evaluated on Fetal loss (early and late). Low-molecular-weight heparin treatment during pregnancy in women with inherited thrombophilia resulted in 0% fetal loss compared to 76.9% in their previous untreated pregnancies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: